Related news from
Fri, 05 Jun 2026 15:30:12 +0000	Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue? Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 05 Jun 2026 13:55:02 +0000	Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tue, 02 Jun 2026 12:00:00 +0000	Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies CONSHOHOCKEN, Pa., June 02, 2026--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite’s U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel).
Mon, 01 Jun 2026 23:11:42 +0000	Is Cencora’s New CFO, $2 Billion Buyback, and Lawsuit Trio Altering The Investment Case For Cencora (COR)? Cencora has appointed Eva C. Boratto as Executive Vice President and Chief Financial Officer effective June 29, 2026, announced a share repurchase program of up to US$2.00 billion, and is facing a new California labor class action lawsuit. The combination of a seasoned healthcare-focused finance leader joining the company and a very large buyback authorization creates an important moment for reassessing Cencora’s capital allocation and governance profile. We’ll now examine how the...
Mon, 01 Jun 2026 18:39:18 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.
Mon, 01 Jun 2026 07:00:00 +0000	LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position LUCENT Biopharma Ltd. ('LUCENT') has appointed Simon Doyle (STEM, NeoHealthHub, Cencora) as CEO with immediate effect. Dr. Matthew Goodman (founder of LUCENT and outgoing CEO) will take-up the position of Chief Medical Officer, remaining a core member of the leadership team at LUCENT.
Wed, 27 May 2026 11:14:26 +0000	Cencora nabs ex-CVS exec as new CFO Eva Boratto, who spent more than a decade at CVS in a variety of finance roles, will join the drug distributor later this summer, Cencora announced Wednesday.
Wed, 27 May 2026 10:55:00 +0000	Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer CONSHOHOCKEN, Pa., May 27, 2026--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition.
Thu, 21 May 2026 20:30:00 +0000	Cencora Announces Updated Fiscal Year 2026 Financial Outlook CONSHOHOCKEN, Pa., May 21, 2026--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company’s previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end of
Tue, 19 May 2026 05:32:55 +0000	3 Market-Beating Stocks to Research Further The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Mon, 18 May 2026 12:36:45 +0000	Cencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-Rating Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The letter emphasizes a long-term, fundamentals-driven investment philosophy, arguing that while stock prices can be volatile in the short run, they ultimately follow underlying earnings growth—illustrated through the “dog and owner” analogy. The […]
Sun, 17 May 2026 21:13:37 +0000	Cencora Legal Probes Test Investor Confidence After Weaker Q2 Revenue Outlook Multiple law firms have launched investigations into Cencora (NYSE:COR) for potential securities law violations following its Q2 2026 results. The company reported revenue that missed prior estimates and reduced its revenue growth forecast, prompting the legal scrutiny. The investigations focus on whether Cencora and its management misled investors around the period of the reported results and updated outlook. Cencora, trading at $257.71 at the last close, is now under a spotlight that goes...
Sat, 16 May 2026 21:56:55 +0000	The Top 5 Analyst Questions From Cencora’s Q1 Earnings Call Cencora’s first quarter results came in below Wall Street’s revenue expectations, and the market responded negatively. Management pointed to several factors behind the underperformance, including faster-than-expected brand-to-biosimilar conversions at a large mail order pharmacy customer, impacts from recent manufacturer price reductions, and lingering effects from the loss of certain customers. CEO Robert Mauch emphasized the resilience of Cencora’s business model, noting ongoing growth in spec
Fri, 15 May 2026 13:25:03 +0000	Wells Fargo Maintains Overweight Rating on Cencora (COR) Cencora, Inc. (NYSE:COR) is one of the 10 Best Depressed Stocks to Buy in 2026. On May 11, 2026, Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Cencora, Inc. (NYSE:COR) to $331 from $429 while maintaining an Overweight rating on the shares. The firm said the magnitude of the slowdown in U.S. […]
Thu, 14 May 2026 17:06:00 +0000	CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell? CAH shares are down 9.4% YTD, but strong specialty drug growth, rising earnings estimates and a raised outlook may signal upside.
Wed, 13 May 2026 14:40:00 +0000	Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment? Cardinal Health's Pharmaceutical & Specialty segment posts strong Q3 growth, but can specialty momentum continue powering earnings?
Sat, 09 May 2026 21:04:45 +0000	Cencora Q2 Earnings Call Highlights Cencora (NYSE:COR) reported higher fiscal second-quarter adjusted earnings and operating income, while management raised its full-year adjusted EPS outlook and said it would resume opportunistic share repurchases. The pharmaceutical distribution and healthcare services company also lowered its full-
Thu, 07 May 2026 16:14:21 +0000	Is Cencora (COR) Prioritizing Margin Expansion Over Growth With Its Raised EPS Outlook and Buybacks? Cencora, Inc. has now reported its fiscal 2026 second-quarter results, with sales of US$78,355.92 million and net income of US$1,641.33 million, alongside a quarterly dividend of US$0.60 per share payable on June 1, 2026. Despite missing consensus revenue and EPS estimates and trimming full-year sales growth guidance, Cencora raised its adjusted EPS outlook and outlined plans for US$1 billion of share repurchases, highlighting a focus on profitability and capital returns even as top-line...
Thu, 07 May 2026 10:08:34 +0000	US Stock Market Today S&P 500 Futures Inch Higher As Inflation Worries Ease The Morning Bull - US Market Morning Update Thursday, May, 7 2026 US stock futures are slightly higher this morning, with E-mini S&P 500 contracts up about 0.1%, as investors balance cooler bond markets, cheaper oil, and fresh US jobs data. The US 10 year Treasury yield is holding near 4.35%, which means borrowing costs for mortgages and companies remain relatively elevated but are not climbing further for now. Hopes of a US Iran peace deal are pulling oil prices lower and easing some...
Wed, 06 May 2026 17:04:56 +0000	Cencora (COR) Q2 2026 Earnings Transcript Robert Mauch: Thank you, Bennett. Hi, everyone, and thank you for joining Cencora's Fiscal 2026 Second Quarter Earnings Call. In our fiscal second quarter, we saw operating income growth in both our U.S. and International Healthcare Solutions segments and delivered adjusted diluted EPS growth of 7.5%.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!